Comparative Pharmacology
Head-to-head clinical analysis: ALCAINE versus EXPAREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAINE versus EXPAREL.
ALCAINE vs EXPAREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, inhibiting nerve impulse conduction and providing prolonged analgesia.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
Local infiltration: up to 266 mg (20 mL) as a single dose; interscalene brachial plexus block: up to 133 mg (10 mL); femoral nerve block: up to 133 mg (10 mL). Maximum dose 266 mg. Administer via slow injection with frequent aspiration.
None Documented
None Documented
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Terminal elimination half-life is 12-48 hours (mean ~24 hours), reflecting prolonged release from the multivesicular liposome depot.
Renal excretion of parent drug and metabolites: <5% unchanged.
Renal (approximately 96% as metabolites, <10% unchanged). Biliary/fecal excretion is negligible.
Category C
Category C
Local Anesthetic
Local Anesthetic